Vanderbilt University

Atherogenics, Inc.

R Daniel Beauchamp

Craig William Lindsley

Alex Gregory Waterson

Russell M Medford

Nipun B Merchant

Robert J Coffey

Bonnie J LaFleur

Rebecca Chinery

Brian E Wadzinski

In one aspect, the invention relates to N-acetamidoalkyl-5-arylisoxazole-3-carboxamide analogs, derivatives thereof, and related compounds, which are useful as mediators of transcriptional induction of E-cadherin; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with E-cadherin activity using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Small molecule mediated transcriptional induction of E-cadherin

In one aspect, the invention relates to N-((arylamino)alkyl)-5-arylisoxazole-3-carboxamide analogs, derivatives thereof, and related compounds, which are useful as mediators of transcriptional induction of E-cadherin; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating disorders associated with E-cadherin activity using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Isoxazole analogs as mediators of transcriptional induction of E-cadherin

The present invention relates to a new tumor suppressor, designated FJX1. Also described are diagnostic, prognostic and therapeutic uses of the FJX1 protein and the FJX1 gene, alone or in combination with traditional cancer therapies.

Four-jointed box (FJX1) in cancer diagnosis and treatment

A method to enhance the cytotoxic activity of an antineoplastic drug comprising administering an effective amount of the antineoplastic drug to a host exhibiting abnormal cell proliferation in combination with an effective cytotoxicity-increasing amount of an antioxidant. The invention also includes a method to decrease the toxicity to an antineoplastic agent or increase the therapeutic index of an antineoplastic agent administered for the treatment of a solid growth of abnormally proliferating cells, comprising administering an antioxidant prior to, with, or following the antineoplastic treatment.

Growing community of inventors

Nashville, TN, United States of America

R Daniel Beauchamp